

RESEARCH

Open Access

# Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis

Ahmed Bettaieb<sup>1</sup>, Yannan Xi<sup>1</sup>, Ellen Hosein<sup>1</sup>, Nicole Coggins<sup>1</sup>, Santana Bachaalany<sup>1</sup>, Florian Wiede<sup>2</sup>, Salvador Perez<sup>3</sup>, Stephen M Griffey<sup>4</sup>, Juan Sastre<sup>3</sup>, Tony Tiganis<sup>2</sup> and Fawaz G Haj<sup>1,5,6\*</sup>

## Abstract

**Background:** Acute pancreatitis (AP) is a common clinical problem whose incidence has been progressively increasing in recent years. Onset of the disease is triggered by intra-acinar cell activation of digestive enzyme zymogens that induce autodigestion, release of pro-inflammatory cytokines and acinar cell injury. T-cell protein tyrosine phosphatase (TCPTP) is implicated in inflammatory signaling but its significance in AP remains unclear.

**Results:** In this study we assessed the role of pancreatic TCPTP in cerulein-induced AP. TCPTP expression was increased at the protein and messenger RNA levels in the early phase of AP in mice and rats. To directly determine whether TCPTP may have a causal role in AP we generated mice with pancreatic TCPTP deletion (panc-TCPTP KO) by crossing TCPTP floxed mice with Pdx1-Cre transgenic mice. Amylase and lipase levels were lower in cerulein-treated panc-TCPTP KO mice compared with controls. In addition, pancreatic mRNA and serum concentrations of the inflammatory cytokines TNF $\alpha$  and IL-6 were lower in panc-TCPTP KO mice. At the molecular level, panc-TCPTP KO mice exhibited enhanced cerulein-induced STAT3 Tyr705 phosphorylation accompanied by a decreased cerulein-induced NF- $\kappa$ B inflammatory response, and decreased ER stress and cell death.

**Conclusion:** These findings revealed a novel role for pancreatic TCPTP in the progression of cerulein-induced AP.

**Keywords:** Acute pancreatitis, TCPTP, Inflammation, STAT3, Knockout mice

## Background

Acute pancreatitis (AP) is often the most common reason for hospitalization from gastrointestinal diseases in Western countries with an unpredictable clinical course [1,2]. The incidence of AP has been progressively increasing in recent years in parallel with its risk factors such as duct obstruction by gallstones, alcohol abuse and obesity [2,3]. Approximately 25% of patients with AP develop a severe disease course that leads to systemic inflammation and multiple organ dysfunction with mortality rates of up to 50% [2,4]. The onset of the disease is triggered by acinar events that involve premature intra-acinar activation of digestive enzymes such as trypsinogen that induces

autodigestion, the release of pro-inflammatory cytokines and acinar cell injury [5-7]. AP remains without specific therapy and understanding the molecular mechanisms underlying its pathogenesis will aid in therapeutic intervention.

Several animal models of AP have been generated to investigate the pathogenesis and to explore potential therapeutic approaches; one of the most common is cerulein-induced pancreatitis [8]. Cerulein is an ortholog of the intestinal hormone cholecystokinin and at high concentrations causes pancreatic secretion of lipase and amylase, death of acinar cells, edema formation and the infiltration of inflammatory cells into the pancreas [9-11], all of which are also observed in human pancreatitis. The mechanism of cerulein action involves activation of NF- $\kappa$ B, the promotion of oxidative stress, and the release of pro-inflammatory cytokines [12,13]. In addition, cerulein treatment modulates pancreatic protein tyrosine

\* Correspondence: fg Haj@ucdavis.edu

<sup>1</sup>Department of Nutrition, University of California Davis, One Shields Ave, 3135 Meyer Hall, Davis, CA 95616, USA

<sup>5</sup>Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA

Full list of author information is available at the end of the article

kinase (PTK) and protein tyrosine phosphatase (PTP) activities [14,15].

The roles of PTPs in AP remain largely unexplored, but some studies have demonstrated altered PTPs expression and activity in murine models of AP. Indeed, cerulein-induced AP in rats is associated with increases in the expression of SHP1 and SHP2 and changes in the dynamics of SHP2 subcellular distribution during the early phase of AP progression [16]. In addition, expression of the endoplasmic reticulum (ER)-anchored protein phosphatase PTP1B is increased in the early phase of cerulein-induced AP [17]. Although these findings suggest a role for PTPs in AP, additional investigation into the contribution of PTPs to the pathogenesis of AP is warranted.

T-cell protein tyrosine phosphatase (TCPTP; encoded by *PTPN2*) is a ubiquitously-expressed PTP [18]. Two splice variants of TCPTP are expressed: a 48 kDa form which is anchored to the ER by a hydrophobic C-terminus, and a 45 kDa variant that lacks the hydrophobic C-terminus and has access to nuclear and cytosolic substrates [19-21]. Several substrates of TCPTP have been identified and include receptor PTKs (RTKs) [19,22,23], non-receptor PTKs such as c-Src [24] and Janus family kinases (JAKs) 1/3 [25], and substrates of PTKs such as signal transducer and activator of transcription (STAT) 1, 3, 5 and 6 [26-30]. Whole-body TCPTP deficiency in mice leads to hematopoietic defects and progressive systemic inflammatory disease [31,32]. More recently, tissue-specific TCPTP deletion helped define the functions of this phosphatase in T cells [33], muscle [34] and brain [30]. However, the function of TCPTP in the pancreas remains unresolved. TCPTP is expressed in the endocrine and exocrine pancreas in mice with stronger expression in islets than the surrounding exocrine tissue [35]. Genome-wide association screens identify *PTPN2* as a susceptibility gene in the pathogenesis of type 1 diabetes [36] whereas others report that TCPTP regulates cytokine-induced  $\beta$ -cell apoptosis [37,38]. In addition, TCPTP regulates ER stress in the glucose-responsive MIN6  $\beta$ -cells and alterations in pancreatic TCPTP expression may serve as an adaptive response for the mitigation of chronic ER stress [35].

In the present study, we investigated the effects of pancreatic TCPTP deletion on cerulein-induced AP. Alterations in systemic inflammation were determined in cerulein-treated versus non-treated control and pancreas-TCPTP knockout mice, and the underlying molecular mechanism investigated.

## Results

### TCPTP expression is increased in the early phase of acute pancreatitis


AP was induced by repetitive intraperitoneal injections of cerulein, an analog of the secretagogue cholecystokinin,

to wild type mice and expression of TCPTP was determined. Immunoblots of pancreatic lysates demonstrated increased TCPTP expression upon cerulein administration (Figure 1A). Expression of the closely related PTP1B and the SH2 domain-containing phosphatase SHP1 was increased upon cerulein administration consistent with published reports [16,17]. In addition, mRNAs of the genes encoding TCPTP, PTP1B and SHP1, as determined by real time RT-PCR, were increased in the pancreas upon cerulein administration (Figure 1B). Similarly, pancreatic TCPTP, SHP1 and PTP1B protein expression was increased in a taurocholate-induced AP rat model [39,40] (Figure 1C). Together, these findings demonstrate that AP is associated with increases in TCPTP at the level of both mRNA and protein.

### Ablation of pancreatic TCPTP mitigates cerulein-induced pancreatitis

The increased expression of TCPTP upon cerulein administration prompted us to investigate the role of this phosphatase in AP. To that end, we crossed TCPTP<sup>fl/fl</sup> mice to those expressing Cre recombinase under the control of pancreatic and duodenal homeobox 1 (Pdx1) promoter to generate mice lacking TCPTP in the (endocrine and exocrine) pancreas [41]. Pancreatic TCPTP knockout mice (hereafter referred to as panc-TCPTP KO) survived to adulthood and did not display gross defects in pancreatic development. Immunoblot analysis of total pancreas lysates demonstrated significant reduction in TCPTP expression in panc-TCPTP KO mice compared with controls (Figure 2A). In addition, TCPTP expression was unchanged in other tissues such as hypothalamus, liver, muscle and adipose tissue (data not shown, and Xi *et al.*, submitted). Similar to wild type mice, panc-TCPTP KO mice exhibited increased expression of SHP1 and PTP1B upon cerulein administration (Additional file 1: Figure S1). Thus, this mouse model provides efficient TCPTP deletion in the pancreas enabling the determination of TCPTP contribution to pancreatitis.

To clarify the significance of TCPTP during AP, we determined the severity of cerulein-induced pancreatitis in control and panc-TCPTP KO mice. Mice were fasted overnight and cerulein (50  $\mu$ g/kg body weight) administered over 12 h and analyses undertaken 2 h later. Histological analysis (Hematoxylin and Eosin staining) evaluating pathologic changes including edema, cell vacuolation and necrosis did not reveal any overt differences between cerulein-treated and untreated mice in this acute timeframe between treatment and euthanasia (data not shown). However, serum activities of amylase and lipase that are commonly used as markers for pancreatic disease, particularly AP were significantly different between control and panc-TCPTP KO mice with and without cerulein administration. Under basal




**Figure 1 Increased TCPTP expression in acute pancreatitis. A)** Total pancreas lysates of wild type mice that were administered saline (control; Ctr; n = 9) or cerulein (Cer; n = 12) immunoblotted for TCPTP, PTP1B, SHP1 and Tubulin. Bar graph represents expression of TCPTP, PTP1B and SHP1 (normalized to Tubulin) and presented as means  $\pm$  SEM. **B)** *TCPTP*, *PTP1B* and *SHP1* expression as assessed by quantitative real time PCR in the pancreata of wild type mice without (-) (n = 6) and with (+) (n = 8) cerulein administration. For A and B (\*\*;  $P \leq 0.01$ ) indicates significant difference between saline- and cerulein-injected mice. **C)** Total pancreas lysates of rats that were administered saline or taurocholate, sacrificed after 1 and 6 h then immunoblotted for TCPTP, PTP1B, SHP1 and Tubulin. Bar graph represents expression of TCPTP, PTP1B and SHP1 (normalized to Tubulin) and presented as means  $\pm$  SEM. (\*\*;  $P \leq 0.01$ ) indicates significant difference between saline- and taurocholate-injected rats.

conditions, serum amylase and lipase were comparable between control and panc-TCPTP KO mice (Figure 2B). Cerulein administration led to significant increase in amylase and lipase; however pancreatic TCPTP deficiency significantly reduced amylase and lipase after cerulein administration. Comparable findings were observed in two independent cohorts of mice. During AP the activation of NF- $\kappa$ B enhances the release of many pro-inflammatory cytokines such as TNF $\alpha$ , IL-1 $\beta$  and IL-6. TNF $\alpha$ , IL-1 $\beta$  are considered primary cytokines in AP since they initiate and propagate most of the consequences of the systemic inflammatory response [42,43], while IL-6 mediates the acute-phase response [44]. Accordingly, pancreatic mRNA levels of TNF $\alpha$ , IL-6 and IL-1 $\beta$  were increased in control mice after cerulein administration and this was significantly reduced in panc-TCPTP KO (Figure 2C). Similarly, serum levels of TNF $\alpha$  and IL-6 were increased in control mice after cerulein administration and this was significantly reduced in panc-TCPTP KO (Figure 2D). Together,

these data demonstrate that pancreatic TCPTP deficiency mitigates cerulein-induced AP in mice.

#### Pancreatic TCPTP deficiency regulates cerulein-induced STAT3 and MAPKs signaling


To investigate the molecular basis for decreased AP in panc-TCPTP KO mice, we initially determined tyrosyl phosphorylation status of STAT3, a *bona fide* TCPTP substrate [18,26,29,30]. It is noteworthy that ablation of pancreatic STAT3 exacerbates cerulein-induced pancreatitis and demonstrates a protective effect of STAT3 against pancreatitis [45]. STAT3 is activated by phosphorylation at Tyr705 leading to dimerization and relocation to the nucleus to promote gene expression [46]. Immunoblots of total pancreatic lysates revealed significantly increased cerulein-induced STAT3 Tyr705 phosphorylation in panc-TCPTP KO mice compared with controls (Figure 3). Mitogen-activated protein kinases (MAPKs) including ERK1/2, p38 and JNK1/2 are induced



rapidly and transiently during experimental AP in rodents [47]. This activation is believed to be a component of the cellular stress response in the onset of inflammation in the pancreas. Indeed, cerulein administration led to increased phosphorylation of ERK1/2, p38 and JNK in control mice that was significantly lower in panc-TCPTP KO mice (Figure 3). The decreased MAPK activation is in keeping with the reduced cerulein-induced AP and inflammation in panc-TCPTP KO mice. These findings demonstrate increased STAT3 phosphorylation and decreased MAPKs activation in pancreata of cerulein-treated panc-TCPTP KO mice.

#### Pancreatic TCPTP deficiency decreases cerulein-induced NF-κB inflammation, ER stress and cell death

NF-κB is a transcription factor that regulates the inflammatory response and plays a crucial role in the pathogenesis of AP [48,49]. NF-κB is activated early in AP in leukocytes and pancreatic acinar cells [50]. Pro-inflammatory cytokines such as *TNFα* activate the IκB kinase complex (IKK) (composed of three subunits IKKγ, IKKα and IKKβ) to phosphorylate inhibitor of NF-κB (IκB) [51]. IκB phosphorylation triggers its ubiquitination and subsequent degradation, leading to the dissociation of NF-κB dimers (typically composed of RelA/p65




and p50) and their translocation to the nucleus for the activation of transcription [52]. Accordingly, we determined the activation status of components of NF- $\kappa$ B signaling pathway in control and panc-TCPTP KO mice. Cerulein-induced IKK $\alpha$ , I $\kappa$ B $\alpha$  and NF- $\kappa$ Bp65 phosphorylation and NF- $\kappa$ Bp50 expression were attenuated in panc-TCPTP KO mice compared with controls (Figure 4). These data demonstrate a decreased cerulein-induced NF- $\kappa$ B inflammatory response in panc-TCPTP KO mice. This is in keeping with the reduced pancreatic and circulating pro-inflammatory cytokines evident in cerulein-treated panc-TCPTP KO mice.

When the folding capacity of the ER is exceeded, misfolded proteins accumulate and lead to ER stress [53]. Cells use adaptive mechanisms to mitigate ER stress known as the unfolded protein response (UPR) [54]. UPR is triggered by transmembrane sensors such as PKR-like ER-regulated kinase (PERK) that detect unfolded proteins in the ER and convey information through their cytosolic domain [55]. ER stress is implicated in the pathophysiology of pancreatitis [56]. Further, we previously demonstrated that TCPTP knockdown in the glucose-responsive MIN6  $\beta$ -cells attenuated PERK-eIF2 $\alpha$  signaling [35]. In line with these findings, pancreatic TCPTP deficiency attenuated cerulein-induced PERK Thr980 and eukaryotic translation initiation factor 2 $\alpha$  (eIF2 $\alpha$ ) Ser51 phosphorylation compared with controls (Figure 5). The UPR is deployed by cells as a compensatory mechanism to restore

homeostasis, but if it fails then apoptosis commences [57]. After exposure to apoptotic stimuli, cells activate initiator Caspases (Caspases 8 and 9) that proteolytically cleave and activate effector Caspases (Caspases 3 and 7) to dismantle dying cells [58,59]. Accordingly, we assessed cerulein-induced expression of initiator and effector Caspases in control versus panc-TCPTP KO mice. Cerulein caused pro-Caspases 8, 9 and 3 cleavage and cleavage of poly ADP ribose polymerase (PARP) (Figure 5). TCPTP deficiency decreased cleaved Caspase 8, 9 and 3 expression as well as PARP indicative of decreased apoptosis (Figure 5). Collectively, these findings demonstrate decreased inflammatory signaling, and decreased ER stress and cell death upon pancreatic TCPTP deficiency during the early phase of cerulein-induced AP.

## Discussion

The multistep development of AP involves a complex cascade of local and systemic events that occur in response to stress by the acinar cells, but the underlying cellular and molecular mechanisms are not well understood. In this study we investigated the role of TCPTP in AP using a cerulein-induced mouse model. We demonstrated increased TCPTP mRNA and protein expression during the early phase of AP. Importantly, pancreatic TCPTP deficiency in mice mitigated the effects of cerulein-induced AP. At the molecular level, panc-




TCPTP KO mice exhibited enhanced cerulein-induced STAT3 tyrosyl phosphorylation, decreased NF-κB inflammatory response, and decreased ER stress and cell death. These findings uncover a novel role for pancreatic TCPTP and suggest that its pharmacological inhibition may be of value for treating AP.

Alterations in gene and protein expression during the initiation phase of AP play an important role in the development and severity of the disease [60]. In this regard, we report an increase in TCPTP expression in a cerulein-induced AP mouse model. This model was employed since secretagogue-induced pancreatitis, elicited by administration of supramaximally stimulating dose of cerulein, is the most well characterized of the pancreatitis models and has characteristics that are similar to those of human pancreatitis [8]. Using the cerulein-induced model, it was demonstrated that the expression of the SH2 domain containing phosphatases, SHP2 and SHP1 increased in AP in rats [16]. While the increase in SHP2 expression was observed in three different *in vivo* models that of SHP1 was specific to the cerulein-induced model [16]. In this study, we additionally confirmed the increased expression of TCPTP using taurocholate-treated rats thereby establishing that its expression pattern in pancreatitis is not specific to one rodent model. Similar to TCPTP, expression of the closely-related PTP1B was increased in cerulein-induced pancreatitis in mice and rats (Figure 1) [17], in contrast to the differential

expression of these PTPs in the pancreata of mice after chronic high fat feeding [35]. Cerulein administration modulates pancreatic tyrosyl phosphorylation [14,15], highlighting the relevance of this signaling modality to pancreatitis and the need to further investigations on the expression and activities of PTKs and PTPs during the initiation and development of this disease. Further, SHP-1, SHP-2 and PTP1B have all been implicated in the dephosphorylation and inactivation of JAK PTKs [61-63]. Thus, it would be of considerable interest to determine whether the elevated SHP-1, SHP-2 and PTP1B act in concert with TCPTP for the coordinated inactivation of JAK/STAT3 signaling.

Using a genetic approach, we demonstrated that ablation of TCPTP in the pancreas ameliorated the course of AP as shown by the reduced serum amylase and lipase activities, decreased pancreatic *TNFα*, *IL-1β* and *IL-6* expression and decreased serum levels of *TNFα* and *IL-6*. These pro-inflammatory cytokines play a pivotal role in the development and severity of the disease [42-44,64]. *TNFα* exacerbates acinar cell injury and is implicated in the spread of the inflammatory cascade to other organs leading to subsequent systemic complications. In addition, *IL-1β* plays an important role in the development of AP and the inhibition of its production decreases the severity of the disease. Moreover, *IL-6* is a major mediator of the acute-phase response and its levels correlate with the severity of the disease. Suppression of these pro-



inflammatory cytokines could attenuate the severity of pancreatitis [65]. It remains unclear if the decreased expression of such pro-inflammatory cytokines in panc-TCPTP KO mice may be associated with alterations in the expression of anti-inflammatory cytokines such as IL-10. Additional studies are warranted to determine the effects of TCPTP deficiency on cytokines levels and the progression of AP.

Pancreatic TCPTP deficiency modulated cerulein-induced STAT3 phosphorylation, MAPK signaling and the NF-κB inflammatory response. STAT3, a *bona fide* TCPTP substrate [26,29], regulates the expression of genes involved in inflammatory reactions induced in response to tissue injury and infection [66]. Importantly, genetic ablation of pancreatic STAT3 exacerbates the course of cerulein-induced AP demonstrating a protective effect of STAT3 against necrotizing pancreatitis [45].

Thus, it is conceivable that the protective effects of pancreatic TCPTP deficiency in AP might be mediated, at least in part, by increased STAT3 activation. However, it is important to note that TCPTP deficiency impacted on additional signaling pathways that have been implicated previously in pancreatitis. In particular, pancreatic TCPTP deletion correlated with decreased activation of the MAPKs JNK, p38 and ERK1/2 indicative of decreased cellular stress, and is in line with previous studies implicating MAPKs in AP [67-70]. Moreover, the NF-κB inflammatory response, which plays an important role in the early stages of AP pathogenesis [48-50] was also attenuated in panc-TCPTP KO mice. The precise mechanism by which TCPTP-deficiency attenuates MAPK and NF-κB signaling remains unclear, but may be indirect and related to overall reduction in inflammation. Finally, ER stress has also been implicated in the pathophysiology of

pancreatitis; the UPR attenuates alcohol-induced pancreatic damage [56], whereas PERK-deficiency impacts on the viability of the exocrine pancreas [71]. The attenuated PERK-eIF2 $\alpha$  phosphorylation and apoptosis observed herein upon pancreatic TCPTP deficiency are in line with our previous findings implicating STAT3 in the regulation of the UPR in MIN6 cells [35] and likely contribute to the attenuated cerulein-induced pancreatic damage.

Although our studies suggest that the targeted inhibition of TCPTP in the pancreas may represent a plausible approach for combating AP, it is important to note that TCPTP is generally considered to be a negative regulator of the inflammatory response. Mice with a global deficiency in TCPTP die soon after birth from hematopoietic defects [31,72] and the development of progressive systemic inflammatory disease [32]. Moreover, T cell-specific TCPTP KO mice develop an effector/memory T cell phenotype, inflammation and autoimmunity with age [33], whereas TCPTP-deficient T cells promote autoimmunity and colitis when transferred into lymphopenic hosts [73]. These anti-inflammatory effects of TCPTP have been linked with the dephosphorylation of Src family kinases, including Lck to attenuate T cell signaling [33], and c-Src to attenuate TNF signaling [24], as well as the dephosphorylation of JAK1 and JAK3 [25] and varied STAT family members such as STAT1, STAT5 and STAT6 [25,27,28] to attenuate cytokine signaling. To our knowledge the results described in this study are the first to establish TCPTP's capacity to promote the inflammatory response. We suggest that this occurs through the dephosphorylation of its substrate STAT3 [26,29,30], which like TCPTP, acts in a cell-type and tissue-dependent manner to elicit both pro- and anti-inflammatory actions.

In summary, the results presented herein demonstrate a novel role for TCPTP in acute pancreatitis and suggest that interventions designed to specifically inhibit TCPTP in the pancreas may be of value in treating this disease.

## Methods

### Animal studies

TCPTP-floxed (TCPTP<sup>fl/fl</sup>) mice on C57Bl/6J background were generated previously [33,34]. Pdx1-Cre mice on C57Bl/6J background were provided by Dr. D. Melton (Harvard University) [41]. Mice were maintained on a 12 h light-dark cycle in a temperature-controlled facility, with free access to water and food. Mice were fed standard laboratory chow (Purina lab chow, # 5001) at weaning. Genotyping for the TCPTP floxed allele and for the presence of Cre was performed by polymerase chain reaction (PCR), using DNA extracted from tails as previously described [33,34]. Acute pancreatitis was induced in 6 week old control and panc-TCPTP KO mice. Mice were fasted overnight then injected intraperitoneally 12

consecutive times, at 1 h intervals, with cerulein (50  $\mu$ g/kg body weight). DMSO was administered to the control group of mice as a vehicle control for cerulein administration. All animals were sacrificed 2 h after the last injection and blood was collected to determine serum amylase and lipase using ELISA kits (Sigma). Circulating serum cytokines levels were measured using a Multiplex kit from Meso Scale Discovery according to the manufacturer's protocol. Pancreata were rapidly removed then portions were allocated for histology, RNA analysis and biochemistry. All mouse studies were conducted according to federal guidelines and approved by the Institutional Animal Care and Use Committee at University of California Davis.

Male Wistar rats were placed under deep anaesthesia with isoflurane before being treated with a solution of 3.5% sodium taurocholate in 0.9% sodium chloride. Acute pancreatitis was induced by a retrograde infusion of the solution before described. At 1 h, and 6 h after the induction of acute pancreatitis, rats were anaesthetized again and the pancreata were harvested and immediately snap-frozen in liquid nitrogen. Wistar rats were used in accordance with protocols approved by the Ethical Committee for Animal Experimentation and Well-being of the University of Valencia.

### Biochemical analyses

Pancreata were lysed using radio-immunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl, pH: 7.4, 150 mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5 mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate and protease inhibitors). Lysates were clarified by centrifugation at 13,000 rpm for 10 min, and protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce Chemical). Proteins were resolved by SDS-PAGE and transferred to PVDF membranes. Immunoblotting of lysates was performed with antibodies for PTP1B (Abcam), TCPTP, SHP1, pPERK (Thr980), PERK, pEIF2 $\alpha$  (Ser51), pSTAT3 (Tyr705), STAT3, eIF2 $\alpha$ , cleaved Caspases 8, 9 and 3, Tubulin (Santa Cruz), pp38 (Thr180/Tyr182), p38,

**Table 1 List of primers used to quantitate TCPTP, PTP1B, SHP1, IL1- $\beta$ , IL-6 and TNF $\alpha$  expression**

Gene	Forward 5' -> 3'	Reverse 5' -> 3'
IL-1 $\beta$	AGCTTCAGGCAGGCAGTATC	AAGTCCACGGGAAAGACAC
IL-6	ACAACCACGGCCTTCCCTACT	CACGATTTCAGAGAACATGTG
PTP1B	AAGTTCATCATGGGCGACTC	CTGTCTTCATCCCCACAGGT
SHP1	AGCTGGGTCCCAAGGAGTAT	CTTGAGGGTAGAGGCCATGA
TBP	TTGGCTAGGTTTCTGCGGTC	GCCCTGAGCATAAGGTGGAA
TCPTP	AGAGTGGCCAAGTTTCCAGA	CACACCATGAGCCAGAAATG
TNF $\alpha$	GACGTGGAAGTGGCAGAAGAG	TGCCACAAGCAGGAATGAGA



pJNK (Thr183/Tyr185), JNK, p-IKK $\alpha$ / $\beta$  (Ser178/180), IKK $\alpha$ / $\beta$ , pIKK $\alpha$  (Ser32), I $\kappa$ B $\alpha$ , pNF- $\kappa$ Bp65 (Ser536), NF- $\kappa$ Bp65, NF- $\kappa$ Bp50 (Cell signaling). After incubation with appropriate secondary antibodies, proteins were visualized using enhanced chemiluminescence (ECL, Amersham Biosciences). Pixel intensities of immunoreactive bands were quantified using ImageQuant 5.0 software (Molecular Dynamics).

Total RNA was extracted from pancreata using TRIzol reagent (Invitrogen). cDNA was generated using high-capacity cDNA Archive Kit (SuperScript<sup>TM</sup> III Reverse Transcriptase, Invitrogen). TCPTP, PTP1B, SHP1, IL1- $\beta$ , IL-6 and TNF $\alpha$  were assessed by SYBR Green quantitative real time PCR (iCycler, BioRad) using the  $\Delta$ CT method with appropriate primers (Table 1) and normalized to TATA-Box binding protein (TBP).

### Statistical analyses

Data are expressed as means  $\pm$  standard error of the mean (SEM). Single data point comparisons were performed using Tukey's-Kramer HSD analyses using JMP program (SAS Institute). Differences were considered significant at  $P \leq 0.05$  and highly significant at  $P \leq 0.01$ .

### Additional file

**Additional file 1: Figure S1.** PTP1B and SHP1 expression in panc-TCP TP KO mice. Total pancreas lysates of wild type and panc-TCP TP KO mice without (-) and with (+) cerulein administration immunoblotted for PTP1B, SHP1, TCP TP and Tubulin. Bar graph represents expression of PTP1B and SHP1 (normalized to Tubulin) and presented as means  $\pm$  SEM. (\*,  $P < 0.05$ , \*\*,  $P < 0.01$ ) indicates significant difference between saline- and cerulein-injected mice, and (#,  $P < 0.05$ ) indicates significant difference between WT and KO mice.

### Abbreviations

TCPTP: T Cell Protein-Tyrosine Phosphatase; AP: Acute Pancreatitis; STAT3: Signal Transducer and Activator of Transcription 3; PERK: PKR-like ER-Regulated Kinase.

### Competing interests

The authors of this manuscript declare that they have no competing interests.

### Authors' contributions

AB: designed and performed research, analyzed data and revised the manuscript. YX: performed research and revised the manuscript. EH: performed research and revised the manuscript. NC: performed research and revised the manuscript. SB: performed research and revised the manuscript. FW: performed research and revised the manuscript. SP: performed research and revised the manuscript. SG: performed research and revised manuscript JS: contributed reagents and intellectual input and revised the manuscript TT: contributed reagents and intellectual input and revised the manuscript FH: designed research, analyzed data and wrote the manuscript. All authors read and approved the final manuscript.

### Acknowledgments

We thank Dr. Doug Melton (Harvard University) for Pdx1-Cre transgenic mice. This work was supported by research grant from the JDRF (1-2009-337) and NIH grants R56DK084317 and R01DK090492 to F.G.H. Research in the Tiganis laboratory is funded by the National Health and Medical Research Council of

Australia. TT is a NHMRC Principal Research Fellow. Research in the Sastre laboratory is funded by SAF2012-39694.

### Author details

<sup>1</sup>Department of Nutrition, University of California Davis, One Shields Ave, 3135 Meyer Hall, Davis, CA 95616, USA. <sup>2</sup>Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia. <sup>3</sup>Department of Physiology, University of Valencia, 46100 Burjassot, Valencia, Spain. <sup>4</sup>Comprehensive Pathology Laboratory, University of California Davis, Davis, CA 95616, USA. <sup>5</sup>Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. <sup>6</sup>Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.

Received: 14 October 2013 Accepted: 20 February 2014

Published: 10 March 2014

### References

1. Baron TH, Morgan DE: **Acute necrotizing pancreatitis.** *N Engl J Med* 1999, **340**:1412-1417.
2. Jha RK, Ma Q, Sha H, Palikhe M: **Acute pancreatitis: a literature review.** *Med Sci Monit* 2009, **15**:RA147-RA156.
3. Whitcomb DC: **Clinical practice. Acute pancreatitis.** *N Engl J Med* 2006, **354**:2142-2150.
4. Pandol SJ, Saluja AK, Imrie CW, Banks PA: **Acute pancreatitis: bench to the bedside.** *Gastroenterology* 2007, **132**:1127-1151.
5. Saluja AK, Donovan EA, Yamanaka K, Yamaguchi Y, Hofbauer B, Steer ML: **Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B.** *Gastroenterology* 1997, **113**:304-310.
6. Bialek R, Willemer S, Arnold R, Adler G: **Evidence of intracellular activation of serine proteases in acute cerulein-induced pancreatitis in rats.** *Scand J Gastroenterol* 1991, **26**:190-196.
7. Naruse S: **Molecular pathophysiology of pancreatitis.** *Intern Med* 2003, **42**:288-289.
8. Lerch MM, Gorelick FS: **Models of acute and chronic pancreatitis.** *Gastroenterology* 2013, **144**:1180-1193.
9. Jensen RT, Wank SA, Rowley WH, Sato S, Gardner JD: **Interaction of CCK with pancreatic acinar cells.** *Trends Pharmacol Sci* 1989, **10**:418-423.
10. Sato S, Stark HA, Martinez J, Beaven MA, Jensen RT, Gardner JD: **Receptor occupation, calcium mobilization, and amylase release in pancreatic acini: effect of CCK-JMV-180.** *Am J Physiol* 1989, **257**:G202-G209.
11. Willemer S, Elsasser HP, Adler G: **Hormone-induced pancreatitis.** *Eur Surg Res* 1992, **24**(Suppl 1):29-39.
12. Gukovskiy I, Gukovskaya AS, Blinman TA, Zaninovic V, Pandol SJ: **Early NF-kappaB activation is associated with hormone-induced pancreatitis.** *Am J Physiol* 1998, **275**:G1402-G1414.
13. Kim H: **Cerulein pancreatitis: oxidative stress, inflammation, and apoptosis.** *Gut Liver* 2008, **2**:74-80.
14. Lutz MP, Sutor SL, Abraham RT, Miller LJ: **A role for cholecystokinin-stimulated protein tyrosine phosphorylation in regulated secretion by the pancreatic acinar cell.** *J Biol Chem* 1993, **268**:11119-11124.
15. Rivard N, Lebel D, Laine J, Morisset J: **Regulation of pancreatic tyrosine kinase and phosphatase activities by cholecystokinin and somatostatin.** *Am J Physiol* 1994, **266**:G1130-G1138.
16. Sarmiento N, Sanchez-Bernal C, Ayra M, Perez N, Hernandez-Hernandez A, Calvo JJ, Sanchez-Yague J: **Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats.** *Biochim Biophys Acta* 2008, **1782**:271-279.
17. Sarmiento N, Sanchez-Bernal C, Perez N, Sardina JL, Mangas A, Calvo JJ, Sanchez-Yague J: **Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats.** *Pancreas* 2010, **39**:639-645.
18. Tiganis T, Bennett AM: **Protein tyrosine phosphatase function: the substrate perspective.** *Biochem J* 2007, **402**:1-15.
19. Tiganis T, Bennett AM, Ravichandran KS, Tonks NK: **Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase.** *Mol Cell Biol* 1998, **18**:1622-1634.
20. Ibarra-Sanchez MJ, Simoncic PD, Nestel FR, Duplay P, Lapp WS, Tremblay ML: **The T-cell protein tyrosine phosphatase.** *Semin Immunol* 2000, **12**:379-386.

21. Lam MH, Michell BJ, Fodero-Tavoletti MT, Kemp BE, Tonks NK, Tiganis T: **Cellular stress regulates the nucleocytoplasmic distribution of the protein-tyrosine phosphatase TCPTP.** *J Biol Chem* 2001, **276**:37700–37707.
22. Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, Puryer MA, Meng TC, Tonks NK, Tiganis T: **Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP.** *Mol Cell Biol* 2003, **23**:2096–2108.
23. Persson C, Savenhed C, Bourdeau A, Tremblay ML, Markova B, Bohmer FD, Haj FG, Neel BG, Elson A, Heldin CH, Rönnstrand L, Ostman A, Hellberg C: **Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase.** *Mol Cell Biol* 2004, **24**:2190–2201.
24. van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, Tremblay ML, Tiganis T: **Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase.** *Nat Immunol* 2005, **6**:253–260.
25. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ: **The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3.** *Curr Biol* 2002, **12**:446–453.
26. Fukushima A, Loh K, Galic S, Fam B, Shields B, Wiede F, Tremblay ML, Watt MJ, Andrikopoulos S, Tiganis T: **T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis.** *Diabetes* 2010, **59**:1906–1914.
27. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K: **Identification of a nuclear Stat1 protein tyrosine phosphatase.** *Mol Cell Biol* 2002, **22**:5662–5668.
28. Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS: **T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.** *Mol Cell Biol* 2007, **27**:2166–2179.
29. Shields BJ, Wiede F, Gurzov EN, Wee K, Hauser C, Zhu HJ, Molloy TJ, O'Toole SA, Daly RJ, Sutherland RL, Mitchell CA, McLean CA, Tiganis T: **TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.** *Mol Cell Biol* 2013, **33**:557–570.
30. Loh K, Fukushima A, Zhang X, Galic S, Briggs D, Enriori PJ, Simonds S, Wiede F, Reichenbach A, Hauser C, Sims NA, Bence KK, Zhang S, Zhang ZY, Kahn BB, Neel BG, Andrews ZB, Cowley MA, Tiganis T: **Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance.** *Cell Metab* 2012, **14**:684–699.
31. You-Ten KE, Muise ES, Itie A, Michalyszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML: **Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice.** *J Exp Med* 1997, **186**:683–693.
32. Heinonen KM, Nestel FP, Newell EW, Charette G, Seemayer TA, Tremblay ML, Lapp WS: **T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease.** *Blood* 2004, **103**:3457–3464.
33. Wiede F, Shields BJ, Chew SH, Kyprisoudis K, van Vliet C, Galic S, Tremblay ML, Russell SM, Godfrey DI, Tiganis T: **T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.** *J Clin Invest* 2011, **121**:4758–4774.
34. Loh K, Merry TL, Galic S, Wu BJ, Watt MJ, Zhang S, Zhang ZY, Neel BG, Tiganis T: **T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.** *Diabetologia* 2012, **55**:468–478.
35. Bettaieb A, Liu S, Xi Y, Nagata N, Matsuo K, Matsuo I, Chahed S, Bakke J, Keilhack H, Tiganis T, Haj FG: **Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and T cell protein tyrosine phosphatase.** *J Biol Chem* 2011, **286**:9225–9235.
36. Espino-Paisan L, de la Calle H, Fernandez-Arquero M, Figueredo MA, de la Concha EG, Urceley E, Santiago JL: **A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes.** *Immunogenetics* 2011, **63**:255–258.
37. Moore F, Colli ML, Cnop M, Esteve MI, Cardozo AK, Cunha DA, Bugliani M, Marchetti P, Eizirik DL: **PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis.** *Diabetes* 2009, **58**:1283–1291.
38. Santin I, Moore F, Colli ML, Gurzov EN, Marselli L, Marchetti P, Eizirik DL: **PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic beta-cell apoptosis via regulation of the BH3-only protein Bim.** *Diabetes* 2011, **60**:3279–3288.
39. Wittel UA, Wiech T, Chakraborty S, Boss B, Lauch R, Batra SK, Hopt UT: **Taurocholate-induced pancreatitis: a model of severe necrotizing pancreatitis in mice.** *Pancreas* 2008, **36**:e9–e21.
40. Pereda J, Perez S, Escobar J, Arduini A, Asensi M, Serviddio G, Sabater L, Aparisi L, Sastre J: **Obese rats exhibit high levels of fat necrosis and isoprostanes in taurocholate-induced acute pancreatitis.** *PLoS One* 2012, **7**:e44383.
41. Gu G, Dubauskaite J, Melton DA: **Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors.** *Development* 2002, **129**:2447–2457.
42. Norman J: **The role of cytokines in the pathogenesis of acute pancreatitis.** *Am J Surg* 1998, **175**:76–83.
43. Pereda J, Sabater L, Aparisi L, Escobar J, Sandoval J, Vina J, Lopez-Rodas G, Sastre J: **Interaction between cytokines and oxidative stress in acute pancreatitis.** *Curr Med Chem* 2006, **13**:2775–2787.
44. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Ruckauer K, Andreesen R, Farthmann EH, Scholmerich J: **Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis.** *Gastroenterology* 1991, **101**:782–785.
45. Shigekawa M, Hikita H, Kodama T, Shimizu S, Li W, Uemura A, Miyagi T, Hosui A, Kanto T, Hiramatsu N, Tatsumi T, Takeda K, Akira S, Takehara T: **Pancreatic STAT3 protects mice against caerulein-induced pancreatitis via PAPI1 induction.** *Am J Pathol* 2012, **181**:2105–2113.
46. Schindler C, Levy DE, Decker T: **JAK-STAT signaling: from interferons to cytokines.** *J Biol Chem* 2007, **282**:20059–20063.
47. Schafer C, Williams JA: **Stress kinases and heat shock proteins in the pancreas: possible roles in normal function and disease.** *J Gastroenterol* 2000, **35**:1–9.
48. Baumann B, Wagner M, Aleksic T, von Wichert G, Weber CK, Adler G, Wirth T: **Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo.** *J Clin Invest* 2007, **117**:1502–1513.
49. Chen X, Ji B, Han B, Ernst SA, Simeone D, Logsdon CD: **NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response.** *Gastroenterology* 2002, **122**:448–457.
50. Vaquero E, Gukovsky I, Zaninovic V, Gukovskaya AS, Pandolfi SJ: **Localized pancreatic NF-kappaB activation and inflammatory response in taurocholate-induced pancreatitis.** *Am J Physiol Gastrointest Liver Physiol* 2001, **280**:G1197–G1208.
51. Bonizzi G, Karin M: **The two NF-kappaB activation pathways and their role in innate and adaptive immunity.** *Trends Immunol* 2004, **25**:280–288.
52. Yang F, Tang E, Guan K, Wang CY: **IKK beta plays an essential role in the phosphorylation of RelA/p65 on the serine 536 induced by lipopolysaccharide.** *J Immunol* 2003, **170**:5630–5635.
53. Schroder M, Kaufman RJ: **The mammalian unfolded protein response.** *Annu Rev Biochem* 2005, **74**:739–789.
54. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, Arnold SM: **The unfolded protein response in nutrient sensing and differentiation.** *Nat Rev Mol Cell Biol* 2002, **3**:411–421.
55. Ron D, Walter P: **Signal integration in the endoplasmic reticulum unfolded protein response.** *Nat Rev Mol Cell Biol* 2007, **8**:519–529.
56. Lugea A, Tischler D, Nguyen J, Gong J, Gukovsky I, French SW, Gorelick FS, Pandolfi SJ: **Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage.** *Gastroenterology* 2011, **140**:987–997.
57. Eizirik DL, Cardozo AK, Cnop M: **The role for endoplasmic reticulum stress in diabetes mellitus.** *Endocr Rev* 2008, **29**:42–61.
58. Fischer U, Janicke RU, Schulze-Osthoff K: **Many cuts to ruin: a comprehensive update of caspase substrates.** *Cell Death Differ* 2003, **10**:76–100.
59. Dahmer MK: **Caspases-2, -3, and -7 are involved in thapsigargin-induced apoptosis of SH-SY5Y neuroblastoma cells.** *J Neurosci Res* 2005, **80**:576–583.
60. Ji B, Chen XQ, Misek DE, Kuick R, Hanash S, Ernst S, Najarian R, Logsdon CD: **Pancreatic gene expression during the initiation of acute pancreatitis: identification of EGR-1 as a key regulator.** *Physiol Genomics* 2003, **14**:59–72.
61. David M, Chen HE, Goelz S, Larner AC, Neel BG: **Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1.** *Mol Cell Biol* 1995, **15**:7050–7058.
62. Yin T, Shen R, Feng GS, Yang YC: **Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases.** *J Biol Chem* 1997, **272**:1032–1037.

63. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, Salmeen A, Barford D, Tonks NK: **TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B.** *J Biol Chem* 2001, **276**:47771–47774.
64. Bae GS, Kim MS, Jeong J, Lee HY, Park KC, Koo BS, Kim BJ, Kim TH, Lee SH, Hwang SY, Shin YK, Song HJ, Park SJ: **Piperine ameliorates the severity of cerulein-induced acute pancreatitis by inhibiting the activation of mitogen activated protein kinases.** *Biochem Biophys Res Commun* 2011, **410**:382–388.
65. Zhang XP, Zhang L, Chen LJ, Cheng QH, Wang JM, Cai W, Shen HP, Cai J: **Influence of dexamethasone on inflammatory mediators and NF-kappaB expression in multiple organs of rats with severe acute pancreatitis.** *World J Gastroenterol* 2007, **13**:548–556.
66. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: **Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway.** *Cell* 1994, **77**:63–71.
67. Wagner AC, Metzler W, Hofken T, Weber H, Goke B: **p38 map kinase is expressed in the pancreas and is immediately activated following cerulein hyperstimulation.** *Digestion* 1999, **60**:41–47.
68. Hofken T, Keller N, Fleischer F, Goke B, Wagner AC: **Map kinase phosphatases (MKPs) are early responsive genes during induction of cerulein hyperstimulation pancreatitis.** *Biochem Biophys Res Commun* 2000, **276**:680–685.
69. Tapia JA, Ferris HA, Jensen RT, Garcia LJ: **Cholecystokinin activates PYK2/CAKbeta by a phospholipase C-dependent mechanism and its association with the mitogen-activated protein kinase signaling pathway in pancreatic acinar cells.** *J Biol Chem* 1999, **274**:31261–31271.
70. Minutoli L, Altavilla D, Marini H, Passaniti M, Bitto A, Seminara P, Venuti FS, Famulari C, Macri A, Versaci A, Squadrito F: **Protective effects of SP600125 a new inhibitor of c-jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK1/2) in an experimental model of cerulein-induced pancreatitis.** *Life Sci* 2004, **75**:2853–2866.
71. Iida K, Li Y, McGrath BC, Frank A, Cavener DR: **PERK eIF2 alpha kinase is required to regulate the viability of the exocrine pancreas in mice.** *BMC Cell Biol* 2007, **8**:38.
72. Wiede F, Chew SH, van Vliet C, Poulton IJ, Kyparissoudis K, Sasmono T, Loh K, Tremblay ML, Godfrey DI, Sims NA, Tiganis T: **Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice.** *PLoS One* 2012, **7**:e36703.
73. Wiede F, La Gruta NL, Tiganis T: **PTPN2 attenuates T-cell lymphopenia-induced proliferation.** *Nat Commun* 2014, **5**:3073.

doi:10.1186/1478-811X-12-13

**Cite this article as:** Bettaieb *et al.*: Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis. *Cell Communication and Signaling* 2014 **12**:13.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

